Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
Year: 2023
Type: article
Abstract: BACKGROUNDGlobal prevalence of diabetes in 2021 was $537 million adults and is projected to rise to 783.2 million in 2045. 1 Type 2 diabetes (T2D) is commonly associated with cardiovascular (CV) risk factors and co-morbidities, including chronic kidney disease (CKD), CV disease (CVD) and peripheral arterial disease (PAD). 2 PAD is an independent predictor of CV and cerebrovascular events, with greater incidence in patients with versus those without T2D.3 Canagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of CV and kidney events in patients with T2D and high CV risk or nephropathy in the CANVAS Program and CREDENCE trial, respectively.4,5 The CANVAS Program showed significant benefits of
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.15065
Institutions: University of British Columbia, UNSW Sydney, The George Institute for Global Health, Royal North Shore Hospital, The University of Sydney, Royal Prince Alfred Hospital, Institut universitaire de cardiologie et de pneumologie de Québec, University of Freiburg, University Medical Center Freiburg, Janssen Canada (Canada), University College London, Stanford Medicine, Stanford University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
OpenAlex ID: W4361190342